ARS Pharmaceuticals reported second quarter 2026 financial results, announcing $26.2 million in U.S. neffy net product revenue and a total U.S. epinephrine market share of 5%. The company outlined strategic priorities including a shift to targeted provider engagement and significant SG&A cost reductions, aiming for cash flow breakeven by the end of 2027. Interim Phase 2b data for its chronic spontaneous urticaria program is expected in Q1 2027. ARS Pharmaceuticals operates as a biopharmaceutical company commercializing neffy, an epinephrine nasal spray for allergic reactions.

On July 15, 2026, ARS Pharmaceuticals, Inc. announced the immediate resignation of Board member Richard Lowenthal and the termination of Chief Medical Officer Sarina Tanimoto, M.D., without cause. The company agreed to pay Mr. Lowenthal and Dr. Tanimoto one-time bonus payments of $217,350 and $111,780, respectively, subject to a release of claims. ARS Pharmaceuticals, Inc. is a biopharmaceutical company focused on the development and commercialization of therapies for gastrointestinal diseases.

ARS Pharmaceuticals, Inc. announced that its Board of Directors appointed current President Donn Casale as Chief Executive Officer, effective July 7, 2026. Casale also joined the Board as a Class III director with a term ending at the 2029 annual meeting. This appointment replaces Richard Lowenthal, who was terminated without cause effective immediately on July 6, 2026. ARS Pharmaceuticals, Inc. is a biopharmaceutical company.